For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
- Healios Licenses Non-Exclusive Rights for iPSC Line to RxCell
September 26, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Pfizer Japan to Discontinue Ibrance’s Capsule Products
September 22, 2022
- Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
- UCB’s Epilepsy Drug Brivaracetam Hits PIII Goal, Japan Submission Eyed in 2023
September 21, 2022
- Otsuka’s Lupus Nephritis Med Lupkynis Wins European Greenlight
September 21, 2022
- Takeda’s CMV Drug Maribavir Snags EU Panel Backing
September 21, 2022
- Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
- Daiichi Sankyo Apologizes for Arrest of Employee
September 20, 2022
- Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
September 20, 2022
- Daiichi Sankyo Employee Nabbed for Killing Wife with Methanol
September 20, 2022
- Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments
September 16, 2022
- Kyowa Kirin Seeks Palmoplantar Pustulosis Nod for Lumicef in Japan
September 16, 2022
- Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
- Novartis’s Sandimmun Faces Post-Recall Stockout, Re-Supply Expected after Late October
September 15, 2022
- Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
- Eisai on Course towards 500-Billion-Yen Mark in Global Lenvima Sales as Trials Progress: Eisai Official
September 14, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…